Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 7Active not recruiting 5Withdrawn 1Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Burkitt Lymphoma 1

Interventions

Rituximab 30Cyclophosphamide 25Filgrastim 19Methotrexate 15fludarabine phosphate 13Etoposide 13Cytarabine 13Peripheral Blood Stem Cell Transplantation 12Cyclosporine 11Vincristine 10Mycophenolic Acid 10Whole-Body Irradiation 9Antilymphocyte Serum 9Radiotherapy 8Granulocyte Colony-Stimulating Factor 8CT-P10 8fludarabine 7Prednisone 7Doxorubicin 7Dexamethasone 7merphos 6Tacrolimus 6Melphalan 6Calcium Dobesilate 6dexamethasone acetate 5dexamethasone 21-phosphate 5deltacortene 5auricularum 5Methylprednisolone 5Leucovorin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Burkitt Lymphoma × Spinal Puncture × Clear all
NCT04933617 2024-07-09

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
8 enrolled 17 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡